PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
 
BMC Cancer. 2012; 12: 304.
Published online Jul 23, 2012. doi:  10.1186/1471-2407-12-304
PMCID: PMC3418560
Myeloid malignancies: mutations, models and management
Anne Murati,1 Mandy Brecqueville,1 Raynier Devillier,1 Marie-Joelle Mozziconacci,1 Véronique Gelsi-Boyer,1 and Daniel Birnbaumcorresponding author1
1Centre de Recherche en Cancérologie de Marseille, laboratoire d’Oncologie Moléculaire; UMR1068 Inserm, Institut Paoli-Calmettes, 27 Bd. Leï Roure, BP 30059, Marseille, 13273, France
corresponding authorCorresponding author.
Anne Murati: muratia/at/ipc.unicancer.fr; Mandy Brecqueville: brecquevillem/at/ipc.unicancer.fr; Raynier Devillier: devillierr/at/ipc.unicancer.fr; Marie-Joelle Mozziconacci: mozziconaccimj/at/ipc.unicancer.fr; Véronique Gelsi-Boyer: gelsiv/at/ipc.unicancer.fr; Daniel Birnbaum: daniel.birnbaum/at/inserm.fr
Received October 5, 2011; Accepted June 30, 2012.
Abstract
Myeloid malignant diseases comprise chronic (including myelodysplastic syndromes, myeloproliferative neoplasms and chronic myelomonocytic leukemia) and acute (acute myeloid leukemia) stages. They are clonal diseases arising in hematopoietic stem or progenitor cells. Mutations responsible for these diseases occur in several genes whose encoded proteins belong principally to five classes: signaling pathways proteins (e.g. CBL, FLT3, JAK2, RAS), transcription factors (e.g. CEBPA, ETV6, RUNX1), epigenetic regulators (e.g. ASXL1, DNMT3A, EZH2, IDH1, IDH2, SUZ12, TET2, UTX), tumor suppressors (e.g. TP53), and components of the spliceosome (e.g. SF3B1, SRSF2). Large-scale sequencing efforts will soon lead to the establishment of a comprehensive repertoire of these mutations, allowing for a better definition and classification of myeloid malignancies, the identification of new prognostic markers and therapeutic targets, and the development of novel therapies. Given the importance of epigenetic deregulation in myeloid diseases, the use of drugs targeting epigenetic regulators appears as a most promising therapeutic approach.
Articles from BMC Cancer are provided here courtesy of
BioMed Central